New drugs in breast cancer.
The 1990s have seen the emergence of several classes of new efficacious drugs which have become established as treatment for breast cancer. Thus, aromatase inhibitors, taxanes and herceptin have all emerged as potentially valuable therapeutic agents for treatment of advanced breast cancer. Bisphosphonates have found a place in preventing skeletal complications in breast cancer patients with bone metastasis. Tamoxifen has a new role in chemoprevention in patients at high risk of breast cancer. This paper summarises these results.
Iqbal
S
S
Breast Unit Research Group, Western General Hospital, Edinburgh, UK.
Miller
W R
WR
D018943:Anthracyclines / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002784:Cholesterol / Q000378:metabolism; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use; D004967:Estrogens / Q000378:metabolism; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D009362:Neoplasm Metastasis; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000187:drug effects; D013629:Tamoxifen / Q000627:therapeutic use; D043823:Taxoids; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D001952:Bridged-Ring Compounds; D004164:Diphosphonates; D004967:Estrogens; D011960:Receptors, Estrogen; D043823:Taxoids; D013629:Tamoxifen; C080625:taxane; D002784:Cholesterol; D000068878:Trastuzumab